用生物药物治疗的牛皮患者的痴呆风险:一种倾向性得分匹配的基于人口的队列研究
Jen A Barak Levitt1, Michael Ziv2
1Department of Dermatology, Emek Medical Center, Afula, Israel; Ruth and Bruce Rappaport Faculty of Medicine, Technion Institute of Technology, Haifa, Israel. Jen.Levitt.Barak@gmail.com.
Acta dermato-venereologica
|May 14, 2025
概括
针对牛皮的生物疗法,向瘤亡因子-α和互白蛋白,可以显著降低老年人痴呆风险. 这一发现表明,除了皮肤健康之外,还有潜在的神经保护性益处.
科学领域:
- 皮肤病学 皮肤病学
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 牛皮的治疗方法,特别是生物药物,显示出潜在的神经保护作用.
- 翻译研究和动物模型表明,牛皮治疗与痴呆症风险降低之间存在联系.
研究的目的:
- 评估牛皮的生物疗法与痴呆症发病率之间的关联.
- 调查针对炎症途径的特定生物药物是否会影响痴呆风险.
主要方法:
- 在65岁以上患有牛皮的患者进行了回顾性队列研究.
- 比较接受生物疗法后系统治疗和仅接受系统治疗的患者.
- 用于创建可比类组的倾向分数匹配 (n=1766).
主要成果:
- 生物疗法与53%降低痴呆风险相关 (HR 0.47).
- 多变量考克斯模型在对混因素进行调整后证实了痴呆症风险降低 (aHR0.52).
- 即使考虑到年龄和其他因素,这种关联仍然很重要.
结论:
- 针对瘤坏死因子-α,曲蛋白-17,曲蛋白-23的生物疗法可能会降低痴呆风险.
- 这些发现表明牛皮生物学的潜在神经保护性益处.
- 需要进一步的研究来证实这些神经保护作用在临床实践中.
相关概念视频
Alzheimer's Disease: Treatment
132
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
132
T Cell Types and Functions
638
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
638
Dementia
73
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
73
Alzheimer's Disease: Overview
336
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
336
Parkinson's Disease: Treatment
158
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
158
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
101
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
101


